CoChat

Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background There is limited previous research examining the healthcare costs of neovascular age-related macular degeneration (NV-AMD), which constrains our understanding of the economic impact of this condition. With aging populations, this leading cause of rapid vision loss in Western countries is expected to become a pressing health predicament, requiring decision makers to evaluate alternative treatment strategies for AMD.Objective To document the economic burden of bilateral NV-AMD, the late stage of AMD, in elderly patients, from a societal perspective. STUDY DESIGN, SETTING AND PARTICIPANTS: A cross-sectional, observational study surveyed 401 patients with bilateral NV-AMD and 471 non-AMD subjects in Canada, France, Germany, Spain and the UK. Physicians' records and subjects' standardized telephone interviews were used to record medical resource utilization, assistance with daily living and social benefits. Annual bilateral NV-AMD-related socioeconomic costs were calculated in euro, year 2005 values.Main outcome measures Societal costs including direct vision-related medical costs (e.g. treatment of AMD and vision-related equipment), direct non-vision-related medical costs (e.g. medications) and direct non-medical-related costs (e.g. home healthcare and social services) were the main outcome measures.Results The demographic profile of NV-AMD patients was similar across countries; however, co-morbid condition profiles varied. NV-AMD patients reported substantial health-related problems and associated health resource utilization (HRU). In the previous 12 months, 12-22% of patients fell, and half of these patients required medical treatments. More than 20% (range 21-59%) of patients were prescribed vision-enhancing equipment. More than half of the patients (54-81%) were living with a spouse or family member and 19-41% reported receiving assistance for activities of daily living. The average annual societal cost per bilateral NV-AMD patient treated was estimated to be euro 7879 in Canada, euro 7349 in France, euro 12 445 in Germany, euro 5732 in Spain and euro 5300 in the UK, and direct vision-related medical costs accounted for 23-63% of the total cost. Half of the patients were diagnosed with bilateral NV-AMD for <1 year, with an average length of 5 months; there were no statistically significant differences in total annual costs per patient between these patients and those who were diagnosed with bilateral disease for > or =1 year. Estimated annual societal costs of bilateral NV-AMD patients in these countries ranged from euro 268 to euro 1311 million. Estimated annual societal costs of all NV-AMD patients in these countries ranged from euro 671 to euro 3278 million.Conclusions Bilateral NV-AMD imposes significant functional impairment on patients, leading to increased HRU and a high societal cost burden. Differences in national healthcare systems and NV-AMD treatment patterns were reflected in the wide variation of NV-AMD costs across the five surveyed countries. Even though the prevalence rates and per-patient costs varied by country, the societal costs of NV-AMD patients were substantial in each country. Earlier intervention with effective therapies is expected to reduce disease burden and disability associated with NV-AMD and, thus, decrease the overall societal cost.

Overview

Integrity signals

Registry

Crossref · 10.2165/00019053-200826010-00006

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 21 references

Cited by

See all 128

Metadata

Authors
Cruess, A. F., Zlateva, G., Xu, X., Soubrane, G., Pauleikhoff, D., Lotery, A., Mones, J., Buggage, R., Schaefer, C., Knight, T., & Goss, T. F.
Affiliations
  • Dalhousie University (CA)
  • Pfizer (United States) (US)
  • Hôpital Intercommunal de Créteil (FR)
  • St. Franziskus Hospital (DE)
  • University of Southampton (GB)
Corresponding author
Cruess, Alan F
Venue
PharmacoEconomics
Published
2008
Volume
26
Issue
1
Pages
57-73
ISSN
1170-7690 (ISSN-L)
OpenAlex
W2090658196
Cited by
126
References
21
Citations by year
2026: 3 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 8 · 2021: 8 · 2020: 3 · 2019: 19 · 2018: 9 · 2017: 6 · 2016: 4 · 2015: 11 · 2014: 7 · 2013: 3 · 2012: 9
FWCI
7.09
Type
journal article
Language
en
Open access
closed
Locations
  • PharmacoEconomics (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
Keywords
neovascular age-related macular degeneration, economic burden, social costs, health care costs, activities of daily living, falls, social services, comorbidities, cross-national comparison, elderly patients, vision loss, treatment costs, patient-reported outcomes, quality of life, health resource utilization
MeSH terms
Aged, Aged, 80 and over, Canada, Cross-Sectional Studies, Cross-Cultural Comparison, Europe, Female, Health Resources, Humans, Macular Degeneration, Male, Middle Aged, Prospective Studies, Quality of Life, Surveys and Questionnaires, Visual Acuity, Comorbidity, Case-Control Studies, Health Care Costs, Cost of Illness, Sickness Impact Profile, Choroidal Neovascularization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study. https://app.cochat.ai/papers/10.2165/00019053-200826010-00006
The paper
Cruess, A. F., Zlateva, G., Xu, X., Soubrane, G., Pauleikhoff, D., Lotery, A., Mones, J., Buggage, R., Schaefer, C., Knight, T., & Goss, T. F. (2008). Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study. PharmacoEconomics. https://doi.org/10.2165/00019053-200826010-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.